PL1708991T3 - Pochodne sulfonoamidu do leczenia chorób - Google Patents

Pochodne sulfonoamidu do leczenia chorób

Info

Publication number
PL1708991T3
PL1708991T3 PL05702252T PL05702252T PL1708991T3 PL 1708991 T3 PL1708991 T3 PL 1708991T3 PL 05702252 T PL05702252 T PL 05702252T PL 05702252 T PL05702252 T PL 05702252T PL 1708991 T3 PL1708991 T3 PL 1708991T3
Authority
PL
Poland
Prior art keywords
diseases
treatment
sulfonamide derivatives
sulfonamide
derivatives
Prior art date
Application number
PL05702252T
Other languages
English (en)
Inventor
Alan D Brown
Mark E Bunnage
Paul A Glossop
Kim James
Charlotte A L Lane
Russell A Lewthwaite
Ian B Moses
David A Price
Nicholas M Thomson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1708991(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PL1708991T3 publication Critical patent/PL1708991T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL05702252T 2004-01-22 2005-01-12 Pochodne sulfonoamidu do leczenia chorób PL1708991T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
PCT/IB2005/000086 WO2005080313A2 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases
EP05702252A EP1708991B1 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
PL1708991T3 true PL1708991T3 (pl) 2008-02-29

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05702252T PL1708991T3 (pl) 2004-01-22 2005-01-12 Pochodne sulfonoamidu do leczenia chorób

Country Status (30)

Country Link
US (4) US7244766B2 (pl)
EP (1) EP1708991B1 (pl)
JP (1) JP4020954B2 (pl)
AP (1) AP2359A (pl)
AR (1) AR047509A1 (pl)
AT (1) ATE375977T1 (pl)
AU (1) AU2005214153B2 (pl)
BR (1) BRPI0507085A (pl)
CA (1) CA2553789C (pl)
DE (1) DE602005002930T2 (pl)
DK (1) DK1708991T3 (pl)
DO (1) DOP2005000006A (pl)
EA (1) EA011167B1 (pl)
ES (1) ES2293530T3 (pl)
GE (1) GEP20094781B (pl)
MY (1) MY143390A (pl)
NL (1) NL1028087C2 (pl)
NO (1) NO20062983L (pl)
NZ (1) NZ548318A (pl)
OA (1) OA13362A (pl)
PA (1) PA8622001A1 (pl)
PE (1) PE20051136A1 (pl)
PL (1) PL1708991T3 (pl)
PT (1) PT1708991E (pl)
RS (1) RS50561B (pl)
SI (1) SI1708991T1 (pl)
TW (1) TWI341831B (pl)
UA (1) UA84048C2 (pl)
UY (1) UY28721A1 (pl)
WO (1) WO2005080313A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1708991T3 (da) * 2004-01-22 2008-01-14 Pfizer Sulfonamid derivater til behandling af sygdomme
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AU2006271356A1 (en) * 2005-07-18 2007-01-25 Pfizer Limited Process for the preparation of sulfonamide derivatives
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
JP5555255B2 (ja) 2008-12-30 2014-07-23 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療のためのスルホンアミド化合物
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
WO2013021309A1 (en) 2011-08-11 2013-02-14 Pfizer Limited Intermediate and process for the preparation of a sulfonamide derivative
US20230293430A1 (en) 2020-06-26 2023-09-21 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US229058A (en) * 1880-06-22 spencer
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
RU2199532C2 (ru) 1997-06-27 2003-02-27 Фудзисава Фармасьютикал Ко., Лтд. Сульфонамидное соединение
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US20030185700A1 (en) * 2002-03-26 2003-10-02 The Japan Steel Works, Ltd. Heat-resisting steel and method of manufacturing the same
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
DK1708991T3 (da) * 2004-01-22 2008-01-14 Pfizer Sulfonamid derivater til behandling af sygdomme

Also Published As

Publication number Publication date
GEP20094781B (en) 2009-09-25
BRPI0507085A (pt) 2007-06-19
EA011167B1 (ru) 2009-02-27
EP1708991A2 (en) 2006-10-11
ES2293530T3 (es) 2008-03-16
WO2005080313A2 (en) 2005-09-01
CA2553789A1 (en) 2005-09-01
MY143390A (en) 2011-05-13
AU2005214153A1 (en) 2005-09-01
SI1708991T1 (sl) 2008-02-29
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17
US20050182091A1 (en) 2005-08-18
NL1028087C2 (nl) 2006-05-09
UY28721A1 (es) 2005-08-31
US7528170B2 (en) 2009-05-05
DE602005002930T2 (de) 2008-07-24
JP4020954B2 (ja) 2007-12-12
EA200601223A1 (ru) 2006-12-29
AP2006003669A0 (en) 2006-06-30
US7767715B2 (en) 2010-08-03
NL1028087A1 (nl) 2005-07-25
EP1708991B1 (en) 2007-10-17
AP2359A (en) 2012-01-30
DOP2005000006A (es) 2005-07-31
DE602005002930D1 (de) 2007-11-29
US20100273758A1 (en) 2010-10-28
US8013019B2 (en) 2011-09-06
NO20062983L (no) 2006-07-24
US20080267970A1 (en) 2008-10-30
PE20051136A1 (es) 2006-02-18
TWI341831B (en) 2011-05-11
ATE375977T1 (de) 2007-11-15
UA84048C2 (ru) 2008-09-10
JP2007518789A (ja) 2007-07-12
CA2553789C (en) 2011-07-19
AR047509A1 (es) 2006-01-25
WO2005080313A3 (en) 2005-12-01
PT1708991E (pt) 2007-12-14
RS50561B (sr) 2010-05-07
US20090197912A1 (en) 2009-08-06
OA13362A (en) 2007-04-13
DK1708991T3 (da) 2008-01-14
TW200530165A (en) 2005-09-16
PA8622001A1 (es) 2005-08-30
WO2005080313A9 (en) 2006-08-31
AU2005214153B2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
HUE050998T2 (hu) Gyógyszerek fibrotikus betegségek kezelésére
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
HRP20160866T1 (hr) Postupci primjene hipoglikemijskih sredstava
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
DK1962869T3 (da) Behandling af luftvejssygdomme
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
DE602004011679D1 (de) Behandelung von Störungen
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases
IL176564A0 (en) Sulfonamide derivatives for the treatment of diseases
SE0403119D0 (sv) Therapeutic agents
SE0400718D0 (sv) Therapeutic agents
SE0400575D0 (sv) A novel pharmacentical composition for the treatment of skin conditions
DK1904060T3 (da) Anvendelse af phthalocyaninderivater til den ikke-fotodynamisk behandling af sygdomme
SE0402780D0 (sv) Therapeutic agents